Pharmacological Applications of Momordica Charantia in Diabetes Management

Momordica charantia, commonly known as bitter melon, has long been employed in traditional medicine for its glucose-lowering effects. Modern pharmacological research has identified a diverse array of bioactive constituents, including cucurbitane triterpenoids, flavonoids, saponins and polypeptide factors, which act through multiple mechanisms to modulate glycaemic control. These include enhancement of pancreatic β-cell function and insulin secretion, inhibition of carbohydrate-digesting enzymes such as α-amylase and α-glucosidase, improvement of peripheral glucose uptake via activation of AMP-activated protein kinase pathways, and antioxidative and anti-inflammatory effects that protect against diabetes-related complications. Preclinical studies in rodent models have demonstrated reduction of fasting blood glucose, improved insulin sensitivity and restoration of islet morphology. Emerging evidence also points to favourable modulation of lipid profiles and attenuation of oxidative stress in hepatic and neural tissues. Efforts are under way to optimise extraction methods, standardise dosages and develop delivery systems that preserve bioactivity, with a view to translating these findings into safe, effective nutraceuticals or adjunctive therapies in type 2 diabetes management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Applications of Momordica Charantia in Diabetes Management publication trend

The graph below shows the total number of articles in pharmacological applications of momordica charantia in diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

α-Amylase: Enzyme that catalyses the breakdown of starch into sugars in the digestive tract.

α-Glucosidase: Intestinal enzyme that cleaves disaccharides into absorbable monosaccharides, influencing postprandial glycaemia.

Insulin secretagogue: Substance that stimulates pancreatic β-cells to release insulin.

IC50: Concentration of an inhibitor required to reduce a given biological activity by half, used to gauge potency.

AMP-activated protein kinase (AMPK): Cellular energy sensor that, when activated, enhances glucose uptake and fatty acid oxidation.

References

1. Anti-diabetic properties of traditional herbal concoction containing Eleutherine palmifolia (L.) Merr., Momordica charantia L., and Syzygium polyanthum (Wight.): a bibliometric analysis. Food Production, Processing and Nutrition (2023).
2. Recent Advances in Momordica charantia: Functional Components and Biological Activities. International Journal of Molecular Sciences (2017).
3. In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.). BMC Complementary Medicine and Therapies (2016).
4. Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases. Frontiers in Pharmacology (2019).
5. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complementary Medicine and Therapies (2007).
6. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. Journal of Neuroinflammation (2011).
7. An Optimised Aqueous Extract of Phenolic Compounds from Bitter Melon with High Antioxidant Capacity. Antioxidants (2014).
8. Studies on the antidiabetic activities of Momordica charantia fruit juice in streptozotocin-induced diabetic rats. Pharmaceutical Biology (2017).
9. Exploring Antioxidant and Enzymes (A-Amylase and B-Glucosidase) Inhibitory Activity of Morinda lucida and Momordica charantia Leaves from Benin. Foods (2020).
10. The Management of Diabetes Mellitus Using Medicinal Plants and Vitamins. International Journal of Molecular Sciences (2023).